Cantor Fitzgerald Remains a Buy on Vanda (VNDA)
In a report released yesterday, Olivia Brayer from Cantor Fitzgerald maintained a Buy rating on Vanda, with a price target of $11.00. The company’s shares closed yesterday at $7.03.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brayer covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Insmed, and Vanda. According to TipRanks, Brayer has an average return of 8.1% and a 47.69% success rate on recommended stocks.
In addition to Cantor Fitzgerald, Vanda also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued on December 16. However, today, Jefferies maintained a Hold rating on Vanda (NASDAQ: VNDA).
Based on Vanda’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $56.26 million and a GAAP net loss of $22.59 million. In comparison, last year the company earned a revenue of $47.65 million and had a GAAP net loss of $5.32 million
Read More on VNDA:
Disclaimer & DisclosureReport an Issue
- Vanda motion sickness approval comes with ‘broad’ label, says Cantor
- Vanda Wins FDA Approval for NEREUS Motion Sickness Drug
- Vanda jumps 18% to $8.33 after motion sickness FDA approval
- Vanda receives FDA approval of Nereus for motion sickness
- Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies
